Zymeworks Common Net Worth
Zymeworks Common Net Worth Breakdown | ZYME |
Zymeworks Common Net Worth Analysis
Zymeworks Common's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Zymeworks Common's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Zymeworks Common's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Zymeworks Common's net worth analysis. One common approach is to calculate Zymeworks Common's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Zymeworks Common's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Zymeworks Common's net worth. This approach calculates the present value of Zymeworks Common's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Zymeworks Common's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Zymeworks Common's net worth. This involves comparing Zymeworks Common's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Zymeworks Common's net worth relative to its peers.
Enterprise Value |
|
To determine if Zymeworks Common is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Zymeworks Common's net worth research are outlined below:
| The company reported the previous year's revenue of 76.01 M. Net Loss for the year was (118.67 M) with profit before overhead, payroll, taxes, and interest of 203.78 M. | |
| Zymeworks Common Stock currently holds about 241.83 M in cash with (118.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.18. | |
| Over 99.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Y-mAbs Therapeutics, Inc. Given Consensus Rating of Moderate Buy by Brokerages - MarketBeat |
Zymeworks Common Quarterly Good Will |
|
Zymeworks Common uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Zymeworks Common Stock. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Zymeworks Common's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Zymeworks Common's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Zymeworks Common is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zymeworks Common Stock backward and forwards among themselves. Zymeworks Common's institutional investor refers to the entity that pools money to purchase Zymeworks Common's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Farallon Capital Management, L.l.c. | 2024-09-30 | 1.4 M | State Street Corp | 2024-09-30 | 1.2 M | Nextech Invest Ag | 2024-09-30 | 1.1 M | Tang Capital Management Llc | 2024-09-30 | 1.1 M | Samsara Biocapital, Llc | 2024-09-30 | 1000 K | Prosight Management, Lp | 2024-09-30 | 917.6 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 849.5 K | Bridgeway Capital Management, Llc | 2024-09-30 | 742.6 K | Geode Capital Management, Llc | 2024-09-30 | 713.9 K | Ecor1 Capital, Llc | 2024-09-30 | 13.4 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 5.1 M |
Follow Zymeworks Common's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 993.21 M.Market Cap |
|
Project Zymeworks Common's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (0.26) | (0.28) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.26) | (0.27) |
When accessing Zymeworks Common's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Zymeworks Common's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Zymeworks Common's profitability and make more informed investment decisions.
Please note, the presentation of Zymeworks Common's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zymeworks Common's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Zymeworks Common's management manipulating its earnings.
Evaluate Zymeworks Common's management efficiency
Zymeworks Common Stock has return on total asset (ROA) of (0.1469) % which means that it has lost $0.1469 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2873) %, meaning that it created substantial loss on money invested by shareholders. Zymeworks Common's management efficiency ratios could be used to measure how well Zymeworks Common manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2024, Return On Tangible Assets is expected to decline to -0.23. In addition to that, Return On Capital Employed is expected to decline to -0.28. At present, Zymeworks Common's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.12, whereas Non Currrent Assets Other are forecasted to decline to about 5.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.75 | 3.90 | |
| Tangible Book Value Per Share | 6.21 | 3.29 | |
| Enterprise Value Over EBITDA | (4.50) | (4.72) | |
| Price Book Value Ratio | 1.54 | 1.46 | |
| Enterprise Value Multiple | (4.50) | (4.72) | |
| Price Fair Value | 1.54 | 1.46 | |
| Enterprise Value | 584.7 M | 673.9 M |
Zymeworks Common Stock has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 11.1502 | Revenue 62.2 M | Quarterly Revenue Growth (0.03) | Revenue Per Share 0.831 | Return On Equity (0.29) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zymeworks Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zymeworks Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zymeworks Common insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zymeworks Common Corporate Filings
8K | 21st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 13th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 29th of October 2024 Other Reports | ViewVerify |
Zymeworks Common Earnings per Share Projection vs Actual
Zymeworks Common Corporate Directors
| Thomas Kreudenstein | Director Engineering | Profile | |
| Nina Weisser | Director Therapeutics | Profile | |
| Lota Zoth | Lead Independent Director | Profile | |
| Shrinal Inamdar | Director Relations | Profile |
Already Invested in Zymeworks Common Stock?
The danger of trading Zymeworks Common Stock is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zymeworks Common is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zymeworks Common. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zymeworks Common Stock is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.831 | Quarterly Revenue Growth (0.03) | Return On Assets (0.15) | Return On Equity (0.29) |
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.